2251 related articles for article (PubMed ID: 25719666)
21. Genomic and Epigenomic Landscaping Defines New Therapeutic Targets for Adenosquamous Carcinoma of the Pancreas.
Lenkiewicz E; Malasi S; Hogenson TL; Flores LF; Barham W; Phillips WJ; Roesler AS; Chambers KR; Rajbhandari N; Hayashi A; Antal CE; Downes M; Grandgenett PM; Hollingsworth MA; Cridebring D; Xiong Y; Lee JH; Ye Z; Yan H; Hernandez MC; Leiting JL; Evans RM; Ordog T; Truty MJ; Borad MJ; Reya T; Von Hoff DD; Fernandez-Zapico ME; Barrett MT
Cancer Res; 2020 Oct; 80(20):4324-4334. PubMed ID: 32928922
[TBL] [Abstract][Full Text] [Related]
22. Changing the course of pancreatic cancer--Focus on recent translational advances.
Javle M; Golan T; Maitra A
Cancer Treat Rev; 2016 Mar; 44():17-25. PubMed ID: 26924195
[TBL] [Abstract][Full Text] [Related]
23. Brca2 deficiency and Trp53 deregulation in pancreatic cancer: implications for therapeutic targeting.
Yee NS
Cancer Biol Ther; 2011 Jun; 11(11):969-73. PubMed ID: 21610317
[No Abstract] [Full Text] [Related]
24. Genomic analyses identify molecular subtypes of pancreatic cancer.
Bailey P; Chang DK; Nones K; Johns AL; Patch AM; Gingras MC; Miller DK; Christ AN; Bruxner TJ; Quinn MC; Nourse C; Murtaugh LC; Harliwong I; Idrisoglu S; Manning S; Nourbakhsh E; Wani S; Fink L; Holmes O; Chin V; Anderson MJ; Kazakoff S; Leonard C; Newell F; Waddell N; Wood S; Xu Q; Wilson PJ; Cloonan N; Kassahn KS; Taylor D; Quek K; Robertson A; Pantano L; Mincarelli L; Sanchez LN; Evers L; Wu J; Pinese M; Cowley MJ; Jones MD; Colvin EK; Nagrial AM; Humphrey ES; Chantrill LA; Mawson A; Humphris J; Chou A; Pajic M; Scarlett CJ; Pinho AV; Giry-Laterriere M; Rooman I; Samra JS; Kench JG; Lovell JA; Merrett ND; Toon CW; Epari K; Nguyen NQ; Barbour A; Zeps N; Moran-Jones K; Jamieson NB; Graham JS; Duthie F; Oien K; Hair J; Grützmann R; Maitra A; Iacobuzio-Donahue CA; Wolfgang CL; Morgan RA; Lawlor RT; Corbo V; Bassi C; Rusev B; Capelli P; Salvia R; Tortora G; Mukhopadhyay D; Petersen GM; ; Munzy DM; Fisher WE; Karim SA; Eshleman JR; Hruban RH; Pilarsky C; Morton JP; Sansom OJ; Scarpa A; Musgrove EA; Bailey UM; Hofmann O; Sutherland RL; Wheeler DA; Gill AJ; Gibbs RA; Pearson JV; Waddell N; Biankin AV; Grimmond SM
Nature; 2016 Mar; 531(7592):47-52. PubMed ID: 26909576
[TBL] [Abstract][Full Text] [Related]
25. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
[TBL] [Abstract][Full Text] [Related]
26. BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts.
Lohse I; Borgida A; Cao P; Cheung M; Pintilie M; Bianco T; Holter S; Ibrahimov E; Kumareswaran R; Bristow RG; Tsao MS; Gallinger S; Hedley DW
Br J Cancer; 2015 Jul; 113(3):425-32. PubMed ID: 26180923
[TBL] [Abstract][Full Text] [Related]
27. Targeting DNA damage repair pathways in pancreas cancer.
Crowley F; Park W; O'Reilly EM
Cancer Metastasis Rev; 2021 Sep; 40(3):891-908. PubMed ID: 34403012
[TBL] [Abstract][Full Text] [Related]
28. An unusual genomic variant of pancreatic ductal adenocarcinoma with an indolent clinical course.
Kohutek ZA; Rosati LM; Hong J; Poling J; Attiyeh MA; Makohon-Moore A; Herman JM; Iacobuzio-Donahue CA
Cold Spring Harb Mol Case Stud; 2017 Jul; 3(4):. PubMed ID: 28679692
[TBL] [Abstract][Full Text] [Related]
29. Inactivation of Brca2 cooperates with Trp53(R172H) to induce invasive pancreatic ductal adenocarcinomas in mice: a mouse model of familial pancreatic cancer.
Feldmann G; Karikari C; dal Molin M; Duringer S; Volkmann P; Bartsch DK; Bisht S; Koorstra JB; Brossart P; Maitra A; Fendrich V
Cancer Biol Ther; 2011 Jun; 11(11):959-68. PubMed ID: 21455033
[TBL] [Abstract][Full Text] [Related]
30. Management of BRCA Mutation Carriers With Pancreatic Adenocarcinoma.
Golan T; Hammel P
J Natl Compr Canc Netw; 2021 Apr; 19(4):469-473. PubMed ID: 33845459
[TBL] [Abstract][Full Text] [Related]
31. The role of PARP inhibitors in germline BRCA-associated pancreatic ductal adenocarcinoma.
Moffat GT; O'Reilly EM
Clin Adv Hematol Oncol; 2020 Mar; 18(3):168-179. PubMed ID: 32609666
[TBL] [Abstract][Full Text] [Related]
32. Murine models for familial pancreatic cancer: Histopathology, latency and drug sensitivity among cancers of Palb2, Brca1 and Brca2 mutant mouse strains.
Park D; Shakya R; Koivisto C; Pitarresi JR; Szabolcs M; Kladney R; Hadjis A; Mace TA; Ludwig T
PLoS One; 2019; 14(12):e0226714. PubMed ID: 31877165
[TBL] [Abstract][Full Text] [Related]
33. The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors.
Miller AL; Fehling SC; Garcia PL; Gamblin TL; Council LN; van Waardenburg RCAM; Yang ES; Bradner JE; Yoon KJ
EBioMedicine; 2019 Jun; 44():419-430. PubMed ID: 31126889
[TBL] [Abstract][Full Text] [Related]
34. An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions.
Lowery MA; Kelsen DP; Stadler ZK; Yu KH; Janjigian YY; Ludwig E; D'Adamo DR; Salo-Mullen E; Robson ME; Allen PJ; Kurtz RC; O'Reilly EM
Oncologist; 2011; 16(10):1397-402. PubMed ID: 21934105
[TBL] [Abstract][Full Text] [Related]
35. Mutations in BRCA1, BRCA2, and PALB2, and a panel of 50 cancer-associated genes in pancreatic ductal adenocarcinoma.
Takeuchi S; Doi M; Ikari N; Yamamoto M; Furukawa T
Sci Rep; 2018 May; 8(1):8105. PubMed ID: 29802286
[TBL] [Abstract][Full Text] [Related]
36. Molecular classification as prognostic factor and guide for treatment decision of pancreatic cancer.
Birnbaum DJ; Bertucci F; Finetti P; Birnbaum D; Mamessier E
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):248-255. PubMed ID: 29499330
[TBL] [Abstract][Full Text] [Related]
37. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
38. Rapid Progression of Metastatic Pancreatic Adenocarcinoma During Platinum-Based Therapy in a Patient Harboring a Pathogenic BRCA2 Germline Variant.
Sorscher S; Ramkissoon S
Oncologist; 2021 Nov; 26(11):916-918. PubMed ID: 34309133
[TBL] [Abstract][Full Text] [Related]
39. Should platinum-based chemotherapy be preferred for germline BReast CAncer genes (BRCA) 1 and 2-mutated pancreatic ductal adenocarcinoma (PDAC) patients? A systematic review and meta-analysis.
Rebelatto TF; Falavigna M; Pozzari M; Spada F; Cella CA; Laffi A; Pellicori S; Fazio N
Cancer Treat Rev; 2019 Nov; 80():101895. PubMed ID: 31542591
[TBL] [Abstract][Full Text] [Related]
40. Whole-genome landscape of pancreatic neuroendocrine tumours.
Scarpa A; Chang DK; Nones K; Corbo V; Patch AM; Bailey P; Lawlor RT; Johns AL; Miller DK; Mafficini A; Rusev B; Scardoni M; Antonello D; Barbi S; Sikora KO; Cingarlini S; Vicentini C; McKay S; Quinn MC; Bruxner TJ; Christ AN; Harliwong I; Idrisoglu S; McLean S; Nourse C; Nourbakhsh E; Wilson PJ; Anderson MJ; Fink JL; Newell F; Waddell N; Holmes O; Kazakoff SH; Leonard C; Wood S; Xu Q; Nagaraj SH; Amato E; Dalai I; Bersani S; Cataldo I; Dei Tos AP; Capelli P; Davì MV; Landoni L; Malpaga A; Miotto M; Whitehall VL; Leggett BA; Harris JL; Harris J; Jones MD; Humphris J; Chantrill LA; Chin V; Nagrial AM; Pajic M; Scarlett CJ; Pinho A; Rooman I; Toon C; Wu J; Pinese M; Cowley M; Barbour A; Mawson A; Humphrey ES; Colvin EK; Chou A; Lovell JA; Jamieson NB; Duthie F; Gingras MC; Fisher WE; Dagg RA; Lau LM; Lee M; Pickett HA; Reddel RR; Samra JS; Kench JG; Merrett ND; Epari K; Nguyen NQ; Zeps N; Falconi M; Simbolo M; Butturini G; Van Buren G; Partelli S; Fassan M; ; Khanna KK; Gill AJ; Wheeler DA; Gibbs RA; Musgrove EA; Bassi C; Tortora G; Pederzoli P; Pearson JV; Waddell N; Biankin AV; Grimmond SM
Nature; 2017 Mar; 543(7643):65-71. PubMed ID: 28199314
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
